Annual D&A
$144.75 M
-$11.85 M-7.57%
01 December 2023
Summary:
Sinovac Biotech annual depreciation & amortization is currently $144.75 million, with the most recent change of -$11.85 million (-7.57%) on 01 December 2023. During the last 3 years, it has risen by +$140.71 million (+3485.46%). SVA annual D&A is now -7.57% below its all-time high of $156.60 million, reached on 31 December 2022.SVA Depreciation And Amortization Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly D&A
N/A
01 June 2024
Summary:
Sinovac Biotech quarterly depreciation & amortization is not available.SVA Quarterly D&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM D&A
N/A
01 June 2024
Summary:
Sinovac Biotech TTM depreciation & amortization is not available.SVA TTM D&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
SVA Depreciation And Amortization Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | - | - |
| 3 y3 years | +3485.5% | - | - |
| 5 y5 years | +2718.2% | - | - |
SVA Depreciation And Amortization High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -7.6% | +3485.5% | ||||
| 5 y | 5 years | -7.6% | +3485.5% | ||||
| alltime | all time | -7.6% | >+9999.0% |
Sinovac Biotech Depreciation And Amortization History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2023 | $144.75 M(-7.6%) | - | - |
| Dec 2022 | $156.60 M(+80.3%) | - | - |
| Dec 2021 | $86.83 M(+2050.9%) | - | - |
| Dec 2020 | $4.04 M(-16.2%) | $1.26 M(+272.2%) | $4.04 M(+1.4%) |
| Sept 2020 | - | $338.00 K(-79.1%) | $3.98 M(-19.0%) |
| June 2020 | - | $1.61 M(+95.5%) | $4.92 M(+8.4%) |
| Mar 2020 | - | $826.00 K(-31.4%) | $4.54 M(-5.8%) |
| Dec 2019 | $4.82 M(-6.2%) | $1.20 M(-5.4%) | $4.82 M(+0.6%) |
| Sept 2019 | - | $1.27 M(+3.1%) | $4.79 M(-1.4%) |
| June 2019 | - | $1.24 M(+11.8%) | $4.86 M(-1.3%) |
| Mar 2019 | - | $1.10 M(-6.0%) | $4.92 M(-4.1%) |
| Dec 2018 | $5.14 M(+5.2%) | $1.18 M(-12.4%) | $5.14 M(+29.7%) |
| Sept 2018 | - | $1.34 M(+3.2%) | $3.96 M(+51.3%) |
| June 2018 | - | $1.30 M(-1.2%) | $2.62 M(+98.8%) |
| Mar 2018 | - | $1.32 M(+28.4%) | $1.32 M(-75.2%) |
| Dec 2017 | $4.88 M(-8.1%) | - | - |
| Dec 2016 | $5.31 M(-18.5%) | $1.03 M(-20.1%) | $5.31 M(-6.1%) |
| Sept 2016 | - | $1.28 M(-14.2%) | $5.65 M(-7.0%) |
| June 2016 | - | $1.50 M(-0.5%) | $6.08 M(-4.1%) |
| Mar 2016 | - | $1.50 M(+9.9%) | $6.34 M(-2.8%) |
| Dec 2015 | $6.52 M(-19.6%) | $1.37 M(-19.8%) | $6.52 M(-16.3%) |
| Sept 2015 | - | $1.71 M(-2.7%) | $7.79 M(+13.2%) |
| June 2015 | - | $1.76 M(+4.2%) | $6.88 M(-3.0%) |
| Mar 2015 | - | $1.69 M(-36.0%) | $7.09 M(-12.5%) |
| Dec 2014 | $8.10 M(+26.5%) | $2.64 M(+228.7%) | $8.10 M(+20.2%) |
| Sept 2014 | - | $802.00 K(-59.2%) | $6.74 M(-11.2%) |
| June 2014 | - | $1.97 M(-27.1%) | $7.59 M(+2.4%) |
| Mar 2014 | - | $2.70 M(+111.9%) | $7.41 M(+15.6%) |
| Dec 2013 | $6.41 M | $1.27 M(-22.8%) | $6.41 M(+7.7%) |
| Sept 2013 | - | $1.65 M(-7.8%) | $5.95 M(+9.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2013 | - | $1.79 M(+5.3%) | $5.43 M(+10.0%) |
| Mar 2013 | - | $1.70 M(+108.4%) | $4.93 M(+9.9%) |
| Dec 2012 | $4.49 M(-7.0%) | $814.80 K(-27.7%) | $4.49 M(-8.1%) |
| Sept 2012 | - | $1.13 M(-12.9%) | $4.89 M(+6.8%) |
| June 2012 | - | $1.29 M(+3.3%) | $4.58 M(-6.3%) |
| Mar 2012 | - | $1.25 M(+3.3%) | $4.88 M(+1.2%) |
| Dec 2011 | $4.83 M(+14.0%) | $1.21 M(+48.7%) | $4.83 M(-4.7%) |
| Sept 2011 | - | $815.70 K(-49.1%) | $5.06 M(-1.7%) |
| June 2011 | - | $1.60 M(+34.5%) | $5.15 M(+13.5%) |
| Mar 2011 | - | $1.19 M(-17.7%) | $4.53 M(+7.1%) |
| Dec 2010 | $4.23 M(+89.0%) | $1.45 M(+60.7%) | $4.23 M(+21.8%) |
| Sept 2010 | - | $901.80 K(-8.9%) | $3.47 M(+9.8%) |
| June 2010 | - | $990.10 K(+11.1%) | $3.16 M(+19.6%) |
| Mar 2010 | - | $891.00 K(+28.8%) | $2.65 M(+18.2%) |
| Dec 2009 | $2.24 M(+26.6%) | $691.70 K(+16.9%) | $2.24 M(+11.0%) |
| Sept 2009 | - | $591.70 K(+25.3%) | $2.02 M(+3.8%) |
| June 2009 | - | $472.10 K(-2.4%) | $1.94 M(+4.5%) |
| Mar 2009 | - | $483.70 K(+2.8%) | $1.86 M(+5.2%) |
| Dec 2008 | $1.77 M(+26.2%) | $470.40 K(-9.2%) | $1.77 M(+36.2%) |
| Sept 2008 | - | $517.80 K(+33.3%) | $1.30 M(+66.3%) |
| June 2008 | - | $388.50 K(-0.9%) | $780.60 K(+99.1%) |
| Mar 2008 | - | $392.10 K | $392.10 K |
| Dec 2007 | $1.40 M(+10.6%) | - | - |
| Dec 2006 | $1.27 M(+15.1%) | - | - |
| Dec 2005 | $1.10 M(+22.5%) | - | - |
| Dec 2004 | $899.20 K(+31.5%) | - | - |
| Dec 2003 | $683.80 K(+571.1%) | - | - |
| Apr 2002 | $101.90 K(+459.9%) | - | - |
| Apr 2001 | $18.20 K(+184.4%) | - | - |
| Apr 2000 | $6400.00 | - | - |
FAQ
- What is Sinovac Biotech annual depreciation & amortization?
- What is the all time high annual D&A for Sinovac Biotech?
- What is the all time high quarterly D&A for Sinovac Biotech?
- What is the all time high TTM D&A for Sinovac Biotech?
What is Sinovac Biotech annual depreciation & amortization?
The current annual D&A of SVA is $144.75 M
What is the all time high annual D&A for Sinovac Biotech?
Sinovac Biotech all-time high annual depreciation & amortization is $156.60 M
What is the all time high quarterly D&A for Sinovac Biotech?
Sinovac Biotech all-time high quarterly depreciation & amortization is $2.70 M
What is the all time high TTM D&A for Sinovac Biotech?
Sinovac Biotech all-time high TTM depreciation & amortization is $8.10 M